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Poster Session I S247were detected not by G-banding but by mRT-PCR in 20 patients
and unfavorable aberrations including t(9;22), t(11;19), t(4;11), and
t(1;19) were detected by mRT-PCR, not by G-banding, in 14
patients. On the other hand, mRT-PCR could not detect various
complexities in 55 patients. Unfavorable aberrations detected by
G-banding, not by mRT-PCR, showed relatively poor survival out-
comes in chemotherapy group and transplant group (p 5 0.053 and
0.004, respectively). Favorable aberrations detected by mRT-PCR
should be considered as good prognosis even G-banding technique
did not detect any aberrations (p 5 0.023). However, the difference
has abolished by autologous or allogeneic hematopoietic stem cell
transplantation. mRT-PCR technique can be a complementary
diagnostic tool of acute leukemia when combined with conventional
cytogenetics and the molecular result is predictable for the prognosis
and the resultant survival.254
A PHASE I STUDY OF GEMTUZUMAB OZOGAMICIN IN COMBINATION
WITH A MYELOABLATIVE CONDITIONING (MAC) REGIMEN AND
ALLOSCT IN CHILDREN WITH HIGH-RISK CD331 AML: A NEW TAR-
GETED IMMUNOCHEMOTHERAPY CONDITIONING REGIMEN (GO-BU/CY)
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Background: Children with high-risk AML (induction failure [IF],
re-induction failure after relapse [RIF], refractory relapse [RR],
3rd complete remission [CR3]) have dismal outcomes (overall sur-
vival [OS] 10-20%) (Michallet et al. BMT, 2000; Shenoy et al.
BMT 2008). Over 80% of AML patients express CD33. Gemtuzu-
mab Ozogamicin (GO) alone and in combination with chemother-
apy is safe and active in childhood AML.
Objectives: To determine the safety, maximum tolerated dose
(MTD) and efficacy of GO in combination with busulfan/cyclophos-
phamide (BU/CY) followed by AlloSCT.
Methods:GOwas administered on Day -14 at doses of 3.0, 4.5, 6.0,
7.5 mg/m2, and BU Days -7, -6, -5, -4 at doses of 12.8-16.0 mg/kg,
and CY Days -3, and -2 at doses of 60 mg/kg followed by allogeneic
hematopoietic stem cell transplantation (AlloSCT). GVHDprophy-
laxis consisted of tacrolimus/mycophenolate mofetil.
Results: Twelve patients: 5-IF, 2-RIF, 4-RR,1-CR3; median age:
3yrs (range 1-17) withmedian follow-up of 1379d (939-2305) in alive
patients. Nine UCBT (3 each HLA 6/6-, 5/6-, 4/6-match), 2 MUD
(10/10) and 1 MSD. 3 patients each at GO doses of 3.0, 4.5, 6.0, or
7.5 mg/m2. No dose-limiting toxicities secondary to GO were ob-
served. Day 100 transplant related mortality was 0%. Neutrophil
and platelet engraftment was observed in 92% and 75% of patients
at median day 22 (12-40) and 42 (21-164), respectively. Median
day 130 donor chimerism was 99% (85-100%). The probability of
grade II-IV aGVHD was 42% while cGVHD was 28%. Seven of
12 patients relapsed, 5 have died from progressive disease, 6 year
event-free survival (EFS) and OS was 33% (CI9510-58%) and 50%
(CI9521-73%), respectively.
Conclusion: GO combined with a MAC regimen followed by Al-
loSCT is well-tolerated in children with high-risk AML and is asso-
ciated with improved EFS and OS compared to historical controls.
The safe and tolerable dose of GO at 7.5mg/m2 will be studied in
a phase II clinical trial under an IND.255
OUTCOMES OF PATIENTS WITH AML WHO UNDERGO SECOND
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT OR DONOR
LYMPHOCYTE INFUSION
Ku, G.H.1, Lane, T.A.3, Castro, J.E.2, Mulroney, C.M.2, Ball, E.D.2,
Curtin, P.T.2 1UC San Diego Medical Center, La Jolla, CA; 2UC SanDiego Medical Center, La Jolla, CA; 3UC San Diego Medical Center,
La Jolla, CA
Objective: Second allogeneic hematopoietic stem cell transplants
(SCT) and donor lymphocyte infusions (DLI) are used to treat pa-
tients who relapse after initial SCT. DLI can also be used to induce
graft-versus-host disease (GVHD) or promote donor chimerism. To
better understand prognostic factors in this population, we reviewed
our institutional experience with second allogeneic SCT/DLI in
AML patients.
Methods: We performed a retrospective review of AML patients
who received either a second allogeneic SCT or DLI from 1991
through 2009. Progression-free survival (PFS) and overall survival
(OS) were estimated by the Kaplan-Meier method, with day of sec-
ond HSCT/DLI defined as day 0. The COX proportional hazards
method was used to determine the individual impact of the following
factors at second HSCT/DLI on OS: age, sex, interval from initial
transplant, remission status, stem cell graft (CD341) vs. DLI
(CD31), related vs. unrelated donor, GVHD prophylaxis, and
development of acute or chronic GVHD.
Results: 37 AML patients (20 females, 17 males) received a second
HSCT or DLI. Median age was 53 years (range 24-69). 17 (46%)
patients received stem cells, the rest DLI. Twenty two (50%) had re-
lated donors. Median interval from the initial SCT to second SCT/
DLI was 99 days (range 21-1227).
SecondHSCT/DLIwas performed for relapsed/persistent disease
(79%), graft failure (11%), and poor chimerism (11%). Prior to sec-
ond HSCT/DLI, 34% were in complete remission (CR). After sec-
ondHSCT/DLI, 66% of 32 evaluable patients were in CR. 14 of 34
evaluable patients (41%) developed acute GVHD, while 3 (9%) de-
veloped chronic GVHD. Univariate analysis did not reveal any pa-
tient factors that significantly impacted OS. The estimated median
PFS and OS were 65 days (95% CI 38-106) and 103 days (95% CI
56-165), respectively.
For patients retransplanted/given DLI for relapsed AML, OS at
100 days, 1 year, and 2 years were 48%, 23%, and 12% respectively.
As shown in Table 1, better OS was seen in patients who relapsed.
200 days versus\100 days after initial SCT. Of 32 deaths, 10 (31%)
were treatment related, 21 (66%) were disease related, and 1 (3%)
was unknown.
Table 1. Overall survival following second allogeneic SCT/DLI
stratified by time of relapse after first SCT.
Time of relapse after first SCT 100 Day 1 Year 2 Year<100 days 33% 13% 0%
100-200 days 63% 13% 0%
>200 days 88% 50% 25%Conclusion: A second HSCT or DLI offers a chance at remission
for some AML patients who relapse after prior allogeneic SCT.
However treatment related mortality is high. Further exploration
of additional strategies is needed to optimize outcomes of this group
of patients.256
PHASE I TRIAL OF ESCALATED DOSES OF TARGETED MARROW RADIA-
TION DELIVERED BY TOMOTHERAPY COMBINED WITH ETOPOSIDE
AND CYCLOPHOSPHAMIDE; AN ALLOGENEIC HCT PREPARATIVE REGI-
MEN FOR PATIENTS WITH ADVANCED LEUKEMIA
Stein, A.S., Wong, J., O’Donnell, M.R., Synder, D.S., Palmer, J.M.,
Tsai, N.-C., Parker, P., Farol, L., Spielberger, R., Sahebi, F.,
Kogut, N., Forman, S. City of Hope Medical Center, Duarte, CA
Overall survival (OS) for acute leukemia in relapse (RL) or induc-
tion failure (IF) treated with HSCT is 16-19% [Duval et al
JCO.2010]. While randomized studies have shown a dose response
relationship, with higher doses of radiation resulting in decreased re-
lapse, this benefit is offset by increased mortality. We report the ini-
tial results of a Phase I trial of 12 patients transplanted between 3/
2008 and 7/2010 in which escalated doses of targeted whole body ra-
diation to marrow bearing areas delivered by Tomotherapy on days
-10 to -6 was added to etoposide 60mg/kg [adj bw] day -5 and
S248 Poster Session Icyclophosphamide 100mg/kg [ideal bw] day -3. Radiation was
started at 1200cGy delivered in 150cGy fractions twice a day.
Dose of radiation was escalated in increments of 150cGy using co-
horts of 3 patients until dose limiting toxicity was reached according
to Bearman grading scale. All patients received peripheral stem cells
on day 0. GVHD prophylaxis consists of tacrolimus and sirolimus.
Patient characteristics are as follows: age 33 yrs(20-54); AML 5,
ALL 5, Biphenotypic 2; Disease stage IF 7, 1 RL 5; Donor source
sibling 8, matched unrelated 1, mismatched (1 allele) unrelated do-
nor 3;WBC atHCT1.4(0.2-100.0), blasts in blood 18(0-77%), mar-
row blasts 30(0-95%). Two patients with no marrow blasts had
persistent extramedullary disease at HCT. With a median follow-
up for alive patients of 9.2 months (2.9- 27) the overall survival
and cumulative incidence of relapse at 6 months are 63% (CI 41%;
78%) and 17% (CI 4%; 50%), respectively. Six patients were treated
at 1500cGy without reaching DLT. Four (33%) patients developed
acute GVHD, 1 (8%) developed Grade 3-4. The day 30 and day 100
NRM was 0% and 8%, respectively. Most common toxicity was
grade 2 stomatitis Causes of death were disease progression 3,
GVHD 2 and infection 1.
These preliminary results suggest that 1.) doses of targeted mar-
row radiation delivered by Tomotherapy can be safely escalated to
1500cGy in combination with etoposide and cyclophosphamide
(DLT not reached); and that 2.) a reduction in relapse/progression
can be achieved without increasing NRM in this high risk patient
population. This observation needs to be confirmed in a larger group
of patients.257
EFFECT OF CHROMOSOMAL LESIONS DETECTED BY SNP-ARRAY KARYO-
TYPING ON SURVIVAL AFTER ALLOGENEIC HCT FOR MDS AND AML
Mohan, S.R., Tiu, R.V., Gondek, L.P., O’Keefe, C.L., Kalaycio, M.,
Sobecks, R.M., Copelan, E.A., Maciejewski, J.P. Cleveland Clinic, Cleve-
land, OH
The prognostic value of chromosomal abnormalities identified by
metaphase cytogenetics (MC) in MDS/AML is well-established and
has been incorporated into risk stratification schemes. High density
single nucleotide polymorphism array (SNP-A) is a karyotyping tool
complementary to MC that can detect previously cryptic chromo-
somal lesions, including acquired somatic uniparental disomy
(UPD). We retrospectively analyzed SNP-A results to assess the
prognostic relevance of chromosomal abnormalities detected by
this method in MDS/AML patients (pts) undergoing allogeneic he-
matopoietic cell transplantation (HCT).
38 pts who underwent allogeneic HCT between 2004 and 2009
had pre-HCTblood ormarrow samples available for SNP-A testing.
Cytogenetic analysis was performed on marrow aspirate by standard
metaphase karyotypingmethods.We performed 250K and 6.0 SNP-
A analyses and correlated the results with clinical outcomes. Median
pt age at HCT was 56 years (range 20-70). The indication for HCT
was either MDS (n 5 25, 66%) or AML arising from MDS, and
HCT was performed at a median of 5 months from diagnosis (range
3-41). Donor sources were HLA-identical related (21, 55%), unre-
lated (13, 34%), and cord blood (4, 11%); myeloablative busulfan-
based conditioning regimens were used for 24 pts (62%) and reduced
intensity fludarabine-based conditioning for the remainder.
Unbalanced chromosomal lesions were detected in 45% of pts by
MC and 71% by SNP-A. Acquired somatic UPD, not detectable by
MC,was identified in 26%of pts. The presence of SNP-A abnormal-
ities was associated with a trend toward worse overall survival (OS)
(16 months vs 45, p 5 .11). The group of pts\ 60 years of age dis-
played significantly worseOSwhen SNP-A abnormalities were iden-
tified (7 months vs not reached, p5 .024). HCT patients with UPD
exhibited worse OS (8.8 months vs not reached, p 5 .016) and re-
lapse-free survival (RFS) (6.6 vs 17.6, p 5 .018) than those without
such lesions. None of the other factors analyzed including the num-
ber of prior therapies, HCT donor source, conditioning regimen, or
time from diagnosis to HCT was associated with OS or RFS in uni-
variate analyses. We conclude that the detection of new SNP-A ab-
normalities, particularly UPD, may provide important prognostic
information in pts with MDS/AML undergoing HCT and should
be further investigated.258
METALLOPORYPHYRIN CONTROLS THE DIFFERENTIATION OF HUMAN
PROMYELOCYTIC LEUKEMIC CELLS
Park, J.1, Noh, E.-M.2, Lee, Y.-R.2, Lee, E.-K.2, Hong, J.H.1, Lee, J.H.1,
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Backgroud:Heme oxygenase -1 (HO-1) is an inducible cytoprotec-
tivemolecule, which displays antioxidant, anti-apoptotic and anti-in-
flammatory effects. HO-1 is well induced in leukemia. However,
there is no report about role of HO-1 in leukemia.
Aims:We investigated the involvement of HO-1 in the differentia-
tion of HL-60 cells.
Methods:HO-1 expression was measured by western blot and real-
time PCR.Differentiation ofHL-60 cells was determined byCD11b
expression through flow cytometric analysis.
Results: Dimethylsulfoxide (DMSO), a representative differentia-
tion inducer of HL-60 cells, induced completely decrease HO-1 ex-
pression in a time-dependent manner, but increase CD11b,
indicating that HO-1 might have negative function in DMSO-in-
duced differentiation of HL-60 cells. Zinc protoporphyrin (ZnPP),
a strong inhibitor of HO-1, induced differentiation of HL-60 cells,
as evidenced by a marked increase in the expression of CD11b fol-
lowing ZnPP treatment. In contrast, treatment with cobalt proto-
porphyrin (CoPP), an activator of HO-1, decreased CD11b
expression. ZnPP induced down-regulation ofHO-1 protein expres-
sion in HL-60 cells, while CoPP induced up-regulation. In addition,
ZnPP treatment caused a decrease in pRb and cyclin D1 expression
and an increase in p21 and p27 expression.
Conclusions: These results suggest that down-regulation of HO-1
might be necessary for DMSO-induced HL-60 differentiation. This
study provides the first evidence that HO-1 plays an important role
in DMSO-induced differentiation of HL-60 cells.259
PROGNOSTIC IMPACT OF A MONOSOMAL KARYOTYPE IN PATIENTS
WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC STEM
CELL TRANSPLANTATION
Hemmati, P.G.1, Terwey, T.H.1, le Coutre, P.1, Stieler, J.1,
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Purpose: Allogeneic stem cell transplantation (alloSCT) is a highly
effective treatment for patients (pts) with acute myeloid leukemia
(AML). Recently, the presence of a monosomal karyotype was shown
to confer to a highly unfavorable prognosis in pts with AML treated
with conventional chemotherapy. Therefore, we investigated the
prognostic impact of a monosomal karyotype on the outcome of
pts with AML following alloSCT.
Patients and Methods: We retrospectively analyzed 153 pts with
AML (median age: 45 years, range: 17 – 68 years) who underwent al-
loSCT in complete remission (CR) at our center between 1994 and
2008. 92 pts (82%) had de novo AML, 27 pts (18%) had therapy-re-
lated AML (tAML) or AML evolving from myelodysplastic syn-
drome. As a stem cell source 131 pts (86%) received peripheral
blood stem cells (PBSCs), 22 pts (14%) received bone marrow
(BM). Conditioning consisted of standard myeloablative condition-
ing (MAC) (12 Gy TBI, 2x60mg/kg cyclophosphamide) in 90 pts
(59%). 63 pts (41%) received reduced intensity conditioning (RIC)
(2x4mg busulfan, 6x30 mg/m2 fludarabine, 4x10mg/kg ATG). 10
pts (7%) had a core-binding factor leukemia (CBF group), 64 pts
(41%) were cytogenetically normal (CN group), 19 pts (12%) had
an unfavorable risk MK-negative karyotype (MK- group) and 19
pts (12%) had a highly unfavorable MK-positive karyotype (MK1
group) (Breems et al., JCO 26: 4791-4797).
Results: After a median follow-up of 58 months (range: 13-176
months) for the surviving pts, 86 pts (56%) are alive and in CR.
Causes of death were relapse in 33 pts (22%) or infections/GvHD
in 32 pts (22%). At 3 years projectedOS was 55%, whereas the prob-
ability of relapse or non-relapse mortality (NRM) was 32% or 22%
for the whole cohort. At 3 years patients in theMK1 group had a sta-
tistically significantly lower overall survival (OS) of 25% as opposed
to 49% (MK- group), 66% (CN group), or 67% (CBF-group)
